Therefore, vitexin’s apparent interaction with the VDR/eNOS signaling pathway and the subsequent effects on angiogenesis-dependent osteogenesis further solidifies vitexin’s potential as a novel therapeutic strategy for osteoporosis. The gene discussed is VDR; the disease is osteoporosis.